Press release
Hypogonadism Treatment Market Growth, Trends and Value Chain 2016-2026 by FMI
Hypogonadism refers to diminished activity of reproductive organs producing little or no hormones. In males, hypogonadism refers to the decrease in either of the functions of the testes i.e. sperm production and testosterone production. It affects the men of all ages. While in females, hypogonadism refers to decreased activity of ovaries leading to reduction in the levels of estrogen and progesterone. Hypogonadism may lead to infertility, fatigue, muscle loss, depression, poor concentration and memory and reduced libido. Hypogonadism is classified into two categories namely, primary and secondary hypogonadism, based on the causative factors. Primary hypogonadism (hypergonadotropic hypogonadism) refers to abnormality in the gonads or testicles responsible for low androgen and estrogen levels. Whereas, in secondary hypogonadism (hypogonadotropic hypogonadism), the problem lies in the brain. The hypothalamus and pituitary gland in the brain, which control the gonads, aren’t working properly.HypogonadismTreatment Market: Drivers and Restraints
Lack of sex hormones can lead to other complaints like increased risk of heart disease and osteoporosis, due to thinning of bones. This has led to the growth of hypogonadism treatment market. Moreover, the market has presence of patented brands with huge sales. Hypogonadism incidence will rise with increasing age and increasing incidence of obesity and rheumatoid arthritis. In addition, changing lifestyle habits associated with smoking and increasing stress levels also lead to reduced androgen and estrogen levels. These are some of the driving force for hypogonadism treatment market. However, the entry of generics would lead to sales erosion of the top brands in the market, thus restraining the hypogonadism treatment market to grow to certain extent.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1328
HypogonadismTreatment Market: Segmentation
The hypogonadism treatment market can be segmented based on product type, distribution channel and geography.
Based on product type, hypogonadism treatment market can be segmented as follows:
Testosterone Replacement Therapy
Injection
Patch
Gel
Lozenge
Estrogen Therapy
Progesterone Therapy
Based on distribution channel, hypogonadism treatment market can be segmented as follows:
Hospitals including hospital pharmacies
Clinics
Retail pharmacies
HypogonadismTreatment Market: Overview
The treatment modality for hypogonadism mainly incudes testosterone replacement through exogenous administration. However, for spermatogenesis, gonadotropins are preferred as testosterone is identified to be less effective. In females, estrogen and progesterone hormones are replaced by exogenous administration. Therefore, the market is analyzed based on hormonal replacement therapy as testosterone, gonadotropins, estrogen and progesterone. Pre-menopausal women can benefit from estrogen that comes in pill or patch form. Treatment for males and females is similar if the hypogonadism is due to a tumor on the pituitary gland. Treatment may include radiation, medication or surgery to shrink or remove the tumor.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1328
HypogonadismTreatment Market: Region-wise Outlook
Region wise, the global hypogonadism treatment marketis classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America is the largest market for hypogonadism treatment with the presence of high prevalence of the disease. However, the industry will be experiencing higher demand from the developing regions such as Latin America, Asia-Pacific, Middle-East and Africa.
HypogonadismTreatment Market: Key Players
Some of the key players in the hypogonadism treatment market include Abbott Laboratories, Inc., Bayer AG, Eli Lilly and Company, Merck Serono, Merck & Co., Inc., Actavis, Inc. and Sanofi S.A.
Browse Full Report@ http://www.futuremarketinsights.com/reports/hypogonadism-treatment-market
ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.
CONTACT:
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypogonadism Treatment Market Growth, Trends and Value Chain 2016-2026 by FMI here
News-ID: 352127 • Views: …
More Releases from Future Market Insights
External Anti-infective Preparations Market USD 6,728.7 Million through 2035, Dr …
The global external anti-infective preparations market is on track for sustained growth, with revenues projected to rise from USD 5,412.8 million in 2025 to approximately USD 6,728.7 million by 2035, representing an absolute increase of USD 1,315.9 million and a compound annual growth rate (CAGR) of 2.2%. This expansion is fueled by the increasing prevalence of external infections and the growing demand for localized antimicrobial treatment solutions across hospitals, clinics,…
External Anti-infective Preparations Market USD 6,728.7 Million through 2035, Dr …
The global external anti-infective preparations market is on track for sustained growth, with revenues projected to rise from USD 5,412.8 million in 2025 to approximately USD 6,728.7 million by 2035, representing an absolute increase of USD 1,315.9 million and a compound annual growth rate (CAGR) of 2.2%. This expansion is fueled by the increasing prevalence of external infections and the growing demand for localized antimicrobial treatment solutions across hospitals, clinics,…
External Anti-infective Preparations Market USD 6,728.7 Million through 2035, Dr …
The global external anti-infective preparations market is on track for sustained growth, with revenues projected to rise from USD 5,412.8 million in 2025 to approximately USD 6,728.7 million by 2035, representing an absolute increase of USD 1,315.9 million and a compound annual growth rate (CAGR) of 2.2%. This expansion is fueled by the increasing prevalence of external infections and the growing demand for localized antimicrobial treatment solutions across hospitals, clinics,…
External Anti-infective Preparations Market USD 6,728.7 Million through 2035, Dr …
The global external anti-infective preparations market is on track for sustained growth, with revenues projected to rise from USD 5,412.8 million in 2025 to approximately USD 6,728.7 million by 2035, representing an absolute increase of USD 1,315.9 million and a compound annual growth rate (CAGR) of 2.2%. This expansion is fueled by the increasing prevalence of external infections and the growing demand for localized antimicrobial treatment solutions across hospitals, clinics,…
More Releases for Hypogonadism
Testosterone undecanoate Market 2024 Product Types (Injection, Oral), Applicatio …
The "Testosterone undecanoate Market" report provides key insights into market size, share, growth dynamics, and emerging trends, enabling businesses to make data-driven decisions and enhance their strategies for expansion. It also highlights technological advancements, diverse sales channels, market penetration, production methods, and company revenues, offering a holistic perspective of the market landscape.
Browse Full Report at: https://www.themarketintelligence.com/market-reports/testosterone-undecanoate-market-1495
About Testosterone undecanoate Market:
The global Testosterone undecanoate market size expanded rapidly 687.2 million in 2024 and…
Global Male Hypogonadism Market 2023: North America to Remain Largest Market for …
Male hypogonadism refers to a medical condition in which the male body is unable to produce adequate levels of testosterone, the hormone responsible for the development and maintenance of male sexual characteristics. This condition can have a significant impact on a man's physical and emotional health, including reduced muscle mass, decreased bone density, and decreased
The male hypogonadism market encompasses the pharmaceuticals and therapies used to treat this condition. The…
Global Male Hypogonadism Market 2023: North America to Remain Largest Market for …
Male hypogonadism is a condition in which the body does not produce enough testosterone, the primary male sex hormone. This can lead to a variety of symptoms, including decreased, erectile dysfunction, fatigue, and muscle weakness. Male hypogonadism is typically treated with testosterone replacement therapy (TRT), which can be administered in several forms, such as gels, injections, and pellets.
Request For Free Sample Report of "Male Hypogonadism Market"@ https://www.persistencemarketresearch.com/samples/22303
The global male hypogonadism…
Global Male Hypogonadism Market 2023: North America to Remain Largest Market for …
The male hypogonadism market refers to the segment of the pharmaceuticals industry that deals with the production and sales of treatments for male hypogonadism. Male hypogonadism is a condition characterized by the underproduction of testosterone, the primary male sex hormone. This can lead to a range of symptoms, including low, fatigue, and decreased muscle mass.
The market for male hypogonadism treatments has been growing in recent years, driven by the increasing…
Global Male Hypogonadism Market 2023: North America to Remain Largest Market for …
The Male Hypogonadism Market is an emerging segment in the medical industry. This condition affects millions of men around the world and can have serious implications for their physical and mental health. Treatment options are available to help manage symptoms, but often come with associated side effects. The Male Hypogonadism Market is expected to experience significant growth over the coming years as more therapies become available. Pharmaceutical companies are investing…
Global Male Hypogonadism Market 2023: North America to Remain Largest Market for …
The male hypogonadism market is a segment of the larger pharmaceutical industry that is focused on developing treatments for male hypogonadism, a condition in which the testes do not produce enough testosterone. In 2022, the male hypogonadism market is expected to continue to grow, driven by the increasing prevalence of the condition and the development of new treatments. The market is expected to be worth billions of dollars in 2022, with strong…
